anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Arsenic is a well-known human carcinogen whose environmental exposure via drinking water, food, and air impacts millions of people across the globe. Various mechanisms of arsenic carcinogenesis have been identified, ranging from damage caused by excessive production of free radicals and epigenetic alterations to the generation of cancer stem cells. A growing body of evidence supports the critical involvement of the endoplasmic stress-activated unfolded protein response (UPR) in promoting as well as suppressing cancer development/progression. Various in vitro and in vivo models have also demonstrated that arsenic induces the UPR via activation of the PERK, IRE1α, and ATF6 proteins. In this review, we discuss the mechanisms of arsenic-induced endoplasmic reticulum stress and the role of each UPR pathway in the various cancer types with a focus on the epigenetic regulation and function of the ATF6 protein. The importance of UPR in arsenic carcinogenesis and cancer stem cells is a relatively new area of research that requires additional investigations via various omics-based and computational tools. These approaches will provide interesting insights into the mechanisms of arsenic-induced cancers for prospective target identification and development of novel anti-cancer therapies.
Substantially pure dimers of Apolipoprotein AI-Milano (APO-AI-M/APO AI-M) were isolated from plasma and characterized. Apolipoprotein AI-M dimer can also be produced in a recombinant  Escherichia coli  system. Pharmaceutical compositions comprising the ApoAI-AI-M/ApoAI-M are described. Patients with atherosclerosis or cardiovascular diseases can be treated with the dimer. Medicaments containing the dimer can also be used to prevent thrombosis in different clinical circumstances, both at the arterial and at the venous level. The dimer can also act as a prodrug for the monomer.
PURPOSE:To provide a new compound useful as a carcinostatic, etc. CONSTITUTION:The objective compound of formula I (X is H, OH or of formula II; Y is OH or of formula II; where, excepting that X and Y are of formula II at the same time), e.g. a compound of formula III. The compound of the formula I has the following characteristics: (1) molecular weight and molecular formula: 416 and C21H24N2O7; (2) infrared ray absorption spectrum: given in the figure (KBr); solubility: soluble in methanol and acetonitrile, insoluble in- hexane and water; (3) color reaction: positive to vanillin sulfate; (4) disposition: basic; and (5) appearance and color: pale yellow amorphous powder. This compound can be obtained by inoculating a medium with Streptomyces sp. G324 strain capable of producing the objective compound (FERM BP-3948) followed by aerobic culture.
Patients in group B will be treated with the help of kinesiology taping along with the conventional treatment. Patient will be in prone position with the dorsiflexion of the foot supported on the bed. Fan shaped taping will be applied with 60 - 100 % tension in the centre of the tape. The ends of the tape; the anchor will be applied without any stretch while centre of the tape will be stretched to approximately 60 - 100 %. Length of the tape may vary from person to person depending upon the size of the foot. Patient will be instructed to keep the tape till the next session. Conventional treatment includes icing and stretching of the calf muscles. Icing will be done for the total of 3-5 minutes. Both groups will be given session of 40 min/day, 3 days/week for 4 weeks, assessment will be done at baseline, at the end of 2nd week \& at the end of 4th week.
PURPOSE:To provide the subject new compound useful as a carcinostatic agent having cancer-inhibiting and carcinostatic effect and effective for the prevention and treatment of cancer. CONSTITUTION:The compound of formula I (n is 4-6; R1 to R5 is H, halogen, lower alkyl, etc.), e.g. 5-hydroxy-4-(6-phenyl-hexa-1,3,5-trienyl)-2(5H)-furanone. The compound can be produced by reacting a compound of formula II with a compound of formula III in a solvent (e.g. THF) in the presence of NaOH, etc., to obtain a compound of formula IV, reacting the compound with a phosphonic acid ester and treating the resultant compound of formula V (R is alkyl) with an aqueous solution of sulfuric acid.
The present invention provides for vitamin A derivative selected from the group consisting of retinol, retinyl ester and any combination thereof incorporated into liposomes formed with alkylammonium fatty acid salts, and methods for manufacturing same. The liposomes of the invention may deliver vitamin A derivative materials at the occurrence of a preset triggering condition. Preferred liposomes of the invention are cationic liposomes. The preferred liposomes of the invention are formed with alkylammonium fatty acid salts, e.g., trialkylammonium fatty acid salts of long chain amides. The encapsulated vitamin A derivative is thus stabilized by the liposomes. The present invention thus also provides a method of stabilizing vitamin A derivative be encapsulation in such liposomes. The liposomes of the invention are used to provide topical skin treatment formulations useful in the treatment of skin.
This is randomized, multicenter, parallel-group, double-blind trial that investigates the efficacy and safety of rabeprazole 10mg twice daily over a period of 52 weeks. The 8-week Treatment Period (unblinded) was followed by a 52-week Maintenance Period (blinded). Participants with cure (modified Los Angeles Classification Grade N or Grade M) at the final endoscopy of the Treatment Period were entered into the Maintenance Period. Participants without cure were discontinued from the study. The participants in the Treatment Period were randomized to take Arm C or Arm D at a ratio of 1:1. The non-recurrence rate as endoscopically confirmed at 52 weeks shall be the primary end point, and this shall be examined through a randomized, multicenter, parallel-group, double-blind trial that investigates the efficacy and safety of rabeprazole 10mg twice daily over a period of 52 weeks.
The present invention relates to a method for preparing a fermented deer antler extract having an anti-inflammatory activity, an extract obtained by the method and to the use of such extract. The method comprises :a step (step 1) of adding purified water to chopped deer antler and performing hot water extraction and filtering on the resultant material; a step (step 2) of adding a culture solution for Bacillus sp. strain to the liquid content obtained in step 1 and fermenting the resultant material to obtain a first fermented liquid extract; and a step (step 3) of adding purified water to the solid content of deer antler obtained in the first step, adding a culture solution for Aspergiullus sp. strain to the resultant material and fermenting the resultant material to obtain a second fermented liquid extract. According to the present invention, deer antler extracts can be prepared by the most environmentally-friendly fermentation, destruction of physiological active substance of deer antler is reduced while increasing the content of active ingredient, and productivity can be also improved. Therefore, the method of the present invention can be valuably used as a method for preparing deer antler extracts which may be used in various fields. Particularly, the method of the present invention systematically discloses an anti-inflammatory activity, and therefore, can be suitably and widely used in foods, cosmetics, etc.
An isolated paramyxovirus, a morbillivirus (FmoPV), isolated nucleic acids encoding the genome of FmoPV, isolated amino acid sequences of FmoPV protein, antibodies to FmoPV and its proteins, and uses thereof are provided. In certain embodiments, the modified FmoPV is a feline morbillivirus. A recombinant FmoPV comprising a modified FmoPV gene or gene segments and the use of such virus are provided. The recombinant FmoPV may be used in the prevention and/or treatment of diseases related to FmoPV or as a delivery vector. A diagnostic assay for the FmoPV is provided. In certain embodiments, the FmoPV causes kidney disease. In certain embodiments, the kidney disease is in felines. In certain embodiments, the kidney disease is tubulo interstitial nephritis ("TIN"). A quantitative assay for the detection of the FmoPV, natural or artificial variants, analogs, or derivatives thereof is provided. In certain embodiments, the quantitative assay is reverse transcription and polymerase chain reaction (RT-PCR). A vaccine and a kit containing the vaccine for the prevention and treatment of FmoPV infection are provided. A diagnosis kit that comprises nucleic acid molecules for the detection of the FmoPV is also provided.
BACKGROUND: Many patients in the Intensive Care Unit (ICU) experience delirium. Understanding the patient perspective of delirium is important to improve care and reduce suffering. The aim of our study was to investigate the subjective patient experience of delirium, delirium-related distress, and delirium management in ICU.
METHODS: Our study had a qualitative multicenter design applying individual interviews and thematic analysis. Participants were critically ill adult patients that were determined delirium positive according to validated delirium screening tools during ICU admission. The interviews were conducted after ICU discharge when patients were delirium-free as assessed by the "Rapid clinical test for delirium" (4AT) and able to participate in an interview.
RESULTS: We interviewed 30 patients choosing the main themes deductively: Delirium experience; Delirium related distress; and Delirium management. Despite variations in recollection detail, ICU survivors consistently reported delirium-related distress during and after their ICU stay, manifesting as temporal confusion, misinterpretations, and a sense of distrust towards ICU staff. Delusions were characterized by a blend of factual and fictional elements. Impaired short-term memory hindered communication and intensified feelings of isolation, neglect, and loss of control.
CONCLUSION: The ICU survivors in our study recalled delirium as an unpleasant and frightening experience, often leading to delirium-related distress during and after their ICU stay, indicating the necessity for enhanced assessment and treatment.
The present invention relates to a novel chemokine, referred to herein as chemokine-2 or CK-2, including particular embodiments which are derived from fish such as rainbow trout (Oncorhynchus mykiss). The invention provides novel polypeptides corresponding to CK-2 chemokines, as well as nucleic acids that encode a CK-2 chemokine and antibodies that specifically bind to a CK-2 chemokine. Therapeutic methods for using the novel CK-2 chemokines are also provided. In particular, the invention provides pharmaceutical compositions, such as vaccines, comprising a CK-2 chemokine and an immunogen. The pharmaceutical compositions may be administered to an organism to enhance or activate an immune response to the immunogen. In another embodiment, the invention also relates to a novel screening method for identifying and/or isolating genes whose mRNA is rapidly degraded in a cell by identifying and/or isolating nucleic acids (for example, from a cDNA library) having one or more sequence motifs that are recognized by an endonuclease. The screening methods are particularly useful for identifying and/or isolating genes that encode novel chemokines, cytokines or oncogenes.
BACKGROUND: The Stop Cancer PAIN Trial was a phase III pragmatic stepped wedge cluster randomised controlled trial which compared effectiveness of screening and guidelines with or without implementation strategies for improving pain in adults with cancer attending six Australian outpatient comprehensive cancer centres (n = 688). A system for pain screening was introduced before observation of a 'control' phase. Implementation strategies introduced in the 'intervention' phase included: (1) audit of adherence to guideline recommendations, with feedback to clinical teams; (2) health professional education via an email-administered 'spaced education' module; and (3) a patient education booklet and self-management resource. Selection of strategies was informed by the Capability, Opportunity and Motivation Behaviour (COM-B) Model (Michie et al., 2011) and evidence for each strategy's stand-alone effectiveness. A consultant physician at each centre supported the intervention as a 'clinical champion'. However, fidelity to the intervention was limited, and the Trial did not demonstrate effectiveness. This paper reports a sub-study of the Trial which aimed to identify factors inhibiting or enabling fidelity to inform future guideline implementation initiatives.
METHODS: The qualitative sub-study enabled in-depth exploration of factors from the perspectives of personnel at each centre. Clinical champions, clinicians and clinic receptionists were invited to participate in semi-structured interviews. Analysis used a framework method and a largely deductive approach based on the COM-B Model.
RESULTS: Twenty-four people participated, including 15 physicians, 8 nurses and 1 clinic receptionist. Coding against the COM-B Model identified 'capability' to be the most influential component, with 'opportunity' and 'motivation' playing largely subsidiary roles. Findings suggest that fidelity could have been improved by: considering the readiness for change of each clinical setting; better articulating the intervention's value proposition; defining clinician roles and responsibilities, addressing perceptions that pain care falls beyond oncology clinicians' scopes of practice; integrating the intervention within existing systems and processes; promoting patient-clinician partnerships; investing in clinical champions among senior nursing and junior medical personnel, supported by medical leaders; and planning for slow incremental change rather than rapid uptake.
CONCLUSIONS: Future guideline implementation interventions may require a 'meta-implementation' approach based on complex systems theory to successfully integrate multiple strategies.
TRIAL REGISTRATION: Registry: Australian New Zealand Clinical Trials Registry; number: ACTRN 12615000064505; data: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspxid=367236&isReview=true .
Dehydration, often unnoticed, can occur in adults due to heat-related illnesses, viral infections, and upper respiratory tract infections, leading to deficits in fluids, electrolytes, and energy (FEE), even without diarrhea. This fluid deficit, in turn, impairs immunity at cellular and molecular levels. Physiologically, the immune system rapidly reacts to threats by adjusting its structural permeability, allowing water and small solutes to be passed, facilitated by proteins like aquaporins (AQPs). These AQPs are also essential for immune cell communication and adjustments of the cytoskeleton for functions like chemotaxis and phagocytosis. Apart from hydration, maintaining an optimal intake of essential micronutrients, including vitamins C and E, copper, zinc, and selenium, is also critical for supporting immune function and acting as antioxidants. Transient alterations in immune function caused by acute stressors or nondiarrheal conditions heighten vulnerability to coexisting illnesses, particularly cold and upper respiratory tract infections, while also elevating the likelihood of recurrent health issues. Supplementing fluids with known FEE content according to quality standards and enhanced taste is recommended during acute illness and until complete recovery. Thus, dehydration, caused by various acute conditions, can impair immunity and delay recovery. Prioritizing hydration and nutrition in healthcare and general settings is imperative, even when diarrhea is absent.
Bacteria with improved survival under toxic and oxidative stress and methods of using the same for bioremediation are described. Many bacteria such as  Escherichia coli  have been found to naturally reduce toxic pollutants into a less toxic form, such as by reducing Chromium (VI) to Chromium (III). Reducing such toxins generates damaging reactive oxygen species, so it is important to find a defense for these bacteria against the associated oxidative stress. Trehalose is a small biomolecule that has been shown to protect bacteria from various types of stress by accumulating within the cells. The present invention is directed to bacteria genetically modified to overexpress trehalose biosynthesis genes. The bacteria demonstrate improved viability when challenged with toxins and oxidative stress. The present invention provides inexpensive and beneficial bacteria and methods for environmental remediation.
Critically ill patients are at higher risk for corneal injury and the mechanisms responsible for ocular lubrication and protection can be compromised. However, the literature diverges on which is the best clinical practice for treatment. There is a scale for assessing the risk for corneal injury. Thus, the general objective of this study was to evaluate the risk for developing corneal injury in critically ill patients and the effectiveness of three types of interventions: eye gel, eyedrops and polyethylene film, compared to the control group in its prevention. The specific objectives were: verify the most effective intervention for the prevention of corneal injury from the available literature and provided by: eye gel, eyedrops and polyethylene film compared to the control group who received eye care through randomized controlled clinical trial. Patients and methods: This study was a randomized controlled trial to determine the best care for the prevention of corneal injury from those available on the market (eye drops, eye gel and polyethylene film), compared to a control group (eye care) in the period from 09/07/2013 to 03/15/2014 .
PURPOSE:To provide a Ca antagonistic agent having Ca antagonistic activity and useful for the prevention and remedy of stenocardia, myocardiac infarction, etc., by using ifenprodil known as an agent for improving the symptoms such as headache, depression, etc. as an active component. CONSTITUTION:The objective Ca antagonistic agent contains ifenprodil [chemi cal name: 2-(4-benzylpiperidino)-1-(4-hydroxyphenyl)-propanol] of formula or its salt, as an active component. Although the compound of formula has a skeleton which cannot be found in known Ca antagonistic agent, it has Ca antagonistic activity and can be used as an agent for circulatory system, e.g. for the improvement, prevention or remedy of stenocardia, stenocardiac pain, essential hypertension, congestive cardiac insufficiency, myocardial infarction, arrhythmia, etc. Dose: 10-150mg daily by oral administration.
PURPOSE:To provide a new contraceptive vaccine containing a swine ovum clear zone Zp-4 ingredient as an immunogen and permitting to effectively achieve the contraception. CONSTITUTION:A known swine ovum clear zone Zp-4 ingredient (pzp-4) as a vaccine antigen is prepared into a preparation by a conventional method. For example, the pzp-4 is suspended in a Freund's perfect adjuvant in a concentration of 10-100mug/ml for its preparation. The vaccine is administered at a dose containing 10-100mug of the pzp-4 as a perfect Freund's adjuvant at the first time and as an imperfect Freund's adjuvant at the second time or later several times for each two-four weeks. The vaccine is effectively used for the contraception of man, pets or livestock. A peptide having a specific amino acid sequence and contained in the pzp-4 is useful as an antigen for the contraceptive vaccine.
One open-label, multicenter, Phase 2 study was conducted testing imatinib mesylate in diverse populations of patients with life-threatening diseases associated with Abl, Kit or PDGFR protein tyrosine kinases. This study included 5 patients with ASM treated with 100 mg to 400 mg of imatinib mesylate daily. These 5 patients ranged from 49 to 74 years of age. In addition to these 5 patients, 10 published case reports and case series describe the use of imatinib mesylate in 23 additional patients with ASM aged 26 to 85 years who also received 100 mg to 400 mg of imatinib mesylate daily. 

Cytogenetic abnormalities were evaluated in 20 of the 28 ASM patients treated with imatinib mesylate from the published reports and in the Phase 2 study. Seven of these 20 patients had the FIP1L1-PDGFRα fusion kinase (or CHIC2 deletion). Patients with this cytogenetic abnormality were predominantly males and had eosinophilia associated with their systemic mast cell disease. Two patients had a Kit mutation in the juxtamembrane region (one Phe522Cys and one K509I) and four patients had a D816V c-Kit mutation (not considered sensitive to imatinib mesylate), one with concomitant CML. 

Of the 28 patients treated for ASM, 8 (29%) achieved a complete hematologic response and 9 (32%) a partial hematologic response (PHR) (61% overall response rate). Median duration of imatinib mesylate therapy for the 5 ASM patients in the Phase 2 study was 13 months (range, 1.4 to 22.3 months) and between 1 month and more than 30 months in the responding patients described in the published medical literature. A summary of the response rates to imatinib mesylate in ASM is provided in Table 23. Response durations of literature patients ranged from 1+ to 30+ months.

Table 23: Response in ASM

Imatinib mesylate has not been shown to be effective in patients with less aggressive forms of systemic mastocytosis (SM). Imatinib mesylate is therefore not recommended for use in patients with cutaneous mastocytosis, indolent systemic mastocytosis (smoldering SM or isolated bone marrow mastocytosis), SM with an associated clonal hematological non-mast cell lineage disease, mast cell leukemia, mast cell sarcoma or extracutaneous mastocytoma. Patients that harbor the D816V mutation of c-Kit are not sensitive to imatinib mesylate and should not receive imatinib mesylate.
FIELD: medicine. ^ SUBSTANCE: invention refers to the area of biotechnology. It describes merged polypeptides that possess immune activity against human immunodeficiency virus (HIV). Polypeptides are produced by the merge of HIV proteins Gag, Pol and Nef. Merged polypeptides can be useful for immunogenic compositions and vaccines. It also describes the method for purification of such merged polypeptides and its use in pharmaceutical combinations. The invention can be used in medicine. ^ EFFECT: prevention and treatment of HIV-infection. ^ 27 cl, 21 dwg, 3 tbl, 9 ex
At on-set the children get a medical examination, blood-tests, measurement of height, weight, skin-fold, waist and hip. Children and parents fill out questionnaires on social and educational background as well as motivation and expectations to the treatment. All Children are thereafter randomised into two groups:multi-disciplinary group intervention versus traditional information. The randomisation is stratified according to gender and degree of overweight (135%-145% and \>145%) supposing that the degree of overweight may mirror the difficulties in loosing weight. The experimental intervention consists of one lecture of general nutrition, weekly psychological group sessions for the children followed by physical exercise, and separate bi-monthly group sessions for the parents. After six months children and parents go to separate group sessions once a month for six months. The control group is offered nutritional advice once with a brief follow-up after one month. The height and weight of the children is measured every month, and the fat % is measured with DEXA-scanning at on-set, after six months, and after twelve months